SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C. Interpreting the evidence: choosing between randomized and non-randomized studies. BMJ 1999; 319: 3125.
  • 2
    Venning GR. Identification of adverse reactions to new drugs, II: how were 18 important adverse reactions discovered and with what delays? BMJ 1983; 286: 28992.
  • 3
    Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000; 59: 8419.
  • 4
    Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 254250.
  • 5
    Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al, the European Leflunomide Study Group. Efficacy and safety of leflunomide compared with sulfasalazine in active rheumatoid arthritis: a double-blind, randomized, multicenter trial. Lancet 1999; 353: 25966.
  • 6
    Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 18708.
  • 7
    Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000; 39: 65565.
  • 8
    Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum 2000; 43: 50614.
  • 9
    Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001; 44: 198492.
  • 10
    Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60: 91323.
  • 11
    Wolfe F, Stephenson B, Doyle J. RA patients remain on leflunomide as long as methotrexate in clinical practice: accumulating evidence of long-term tolerability and effectiveness of leflunomide in RA [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S144.
  • 12
    Kalden J, Schattenkirchner M, Sorensen H, Emery P, Deighton C, Rozman B, et al. Five year follow-up: efficacy and safety of leflunomide in patients with active rheumatoid arthritis [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S173.
  • 13
    Van Pelt PA, van Schaardenburg D, Bultink IEM, Dijkmans BAC. High discontinuation rate of treatment with leflunomide in daily practice [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S143.
  • 14
    Miller ML, Morton GL, Anderson LG, Keroack BJ, Radis CD. One-year community based experience with leflunomide in the treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S343.
  • 15
    Geborek G, Crnkic M, Peterson IM, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up program in southern Sweden. Ann Rheum Dis 2002; 61: 7938.
  • 16
    Boyko EJ, Koespell TD, Gaziano JM, Horner RD, Feussner JR. US Department of Veterans Affairs Medical Care System as a resource to epidemiologists. Am J Epidemiol 2000; 151: 30714.
  • 17
    Schiff MH, Strand V, Oed C, Loew-Friedrich I. Leflunomide: efficacy and safety in clinical trials for the treatment of rheumatoid arthritis. Drugs Today (Barc) 2000; 36: 38394.
  • 18
    Weinblatt ME, Kremer J, Coblyn JS, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 13228.
  • 19
    Kremer JM, Caldwell JR, Cannon GW, Genoves M, Cush JJ, Bathon J, et al. The combination of leflunomide and methotrexate in patients with active rheumatoid arthritis who are failing on methotrexate alone: a double-blind placebo controlled study [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S224.
  • 20
    Erra A, Moreno E, Tomas C, Sans X, Arnal C, Barcelo P, et al. Efficacy and safety of leflunomide in rheumatoid arthritis patients: relationship between adverse events and loading dose. Ann Rheum Dis 2002; 61 Suppl I: 379.
  • 21
    Mikuls TR, O'Dell J. The changing face of rheumatoid arthritis therapy: results of serial surveys. Arthritis Rheum 2000; 43: 4645.
  • 22
    Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled phase II study. Arthritis Rheum 1995; 38: 1595603.
  • 23
    Weinblatt ME, Dixon JA, Falchuk KP. Serious liver toxicity in a patient receiving methotrexate and leflunomide. Arthritis Rheum 2000; 43: 260911.
  • 24
    The European Agency for the Evaluation of Medicinal Products. EMEA public statement on leflunomide (Arava): severe and serious hepatic reactions. Accessed August 8, 2002. URL: www.emea.eu.int/pdfs/human/press/pus/561101en.pdf.